According to a recent trial led by a UTHealth Houston researcher, valbenazine, a novel selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is effective in treating chorea, a movement abnormality typically associated with Huntington's disease. Huntington's disease, a rare genetic condition that affects people in their 30s and 40s, causes nerve cells in the brain to break down. About 40,000 people in the United States suffer from this lethal condition, and another 200,000 are in danger of inheriting it.
Although there is no cure, medicines and physical, speech, and occupational therapy can help manage the symptoms. Chorea is caused by Huntington’s disease and is characterized by uncontrollable and erratic movement and cardinal motor symptoms. The findings of a phase 3, randomized, placebo-controlled, and double-blind study, presented in the American Academy of Neurology 2022…
